×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CVM – cel-sci corporation (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CVM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/25
05:29 pm
cvm
CEL-SCI files to sell 1M shares of common stock for holders [Seeking Alpha]
Medium
Report
CEL-SCI files to sell 1M shares of common stock for holders [Seeking Alpha]
10/22
09:15 am
cvm
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
Low
Report
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
10/1
06:00 am
cvm
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Low
Report
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
9/16
07:35 am
cvm
CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation [Yahoo! Finance]
High
Report
CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation [Yahoo! Finance]
9/16
07:30 am
cvm
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
High
Report
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
9/10
09:32 am
cvm
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
Low
Report
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
9/4
09:00 am
cvm
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
Low
Report
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
8/28
04:49 pm
cvm
CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study [Yahoo! Finance]
Low
Report
CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/1
09:13 am
cvm
Form 4 CEL SCI CORP For: Sep 30 Filed by: TALOR EYAL
Neutral
Report
Form 4 CEL SCI CORP For: Sep 30 Filed by: TALOR EYAL
10/1
09:06 am
cvm
Form 4 CEL SCI CORP For: Sep 30 Filed by: PRICHEP PATRICIA B
Neutral
Report
Form 4 CEL SCI CORP For: Sep 30 Filed by: PRICHEP PATRICIA B
10/1
08:59 am
cvm
Form 4 CEL SCI CORP For: Sep 30 Filed by: KERSTEN GEERT R
Neutral
Report
Form 4 CEL SCI CORP For: Sep 30 Filed by: KERSTEN GEERT R
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/3
Form 4 CEL SCI CORP For: Jun 03 Filed by: KERSTEN GEERT R
26.6%
6/10 CEL-SCI Corporation Set to Join Russell 3000® Index 21.7%
4/24 Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment [The Motley Fool] 17.7%
1/13 Form 4 CEL SCI CORP For: Jan 10 Filed by: KERSTEN GEERT R 17.3%
3/13 Cel-Sci Corporation (NASDAQ: CVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 16.5%
2/26 CEL-SCI Corporation Issues Letter to Shareholders 15.0%
4/20 Form 4 CEL SCI CORP For: Apr 20 Filed by: CIPRIANO JOHN 9.7%
5/8 CEL-SCI Corporation Releases Letter to Shareholders 9.7%
2/2 CEL-SCI: Food For Thought Before The Big Day [Seeking Alpha] 8.2%
2/28 CEL-SCI Corporation: Investors' Caution Warranted [Seeking Alpha] 7.9%
6/10 CEL-SCI Corporation Set to Join Russell 3000® Index 21.7%
4/24 Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment [The Motley Fool] 17.7%
1/13 Form 4 CEL SCI CORP For: Jan 10 Filed by: KERSTEN GEERT R 17.3%
3/13 Cel-Sci Corporation (NASDAQ: CVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 16.5%
2/26 CEL-SCI Corporation Issues Letter to Shareholders 15.0%
4/20 Form 4 CEL SCI CORP For: Apr 20 Filed by: CIPRIANO JOHN 9.7%
5/8 CEL-SCI Corporation Releases Letter to Shareholders 9.7%
2/2 CEL-SCI: Food For Thought Before The Big Day [Seeking Alpha] 8.2%
2/28 CEL-SCI Corporation: Investors' Caution Warranted [Seeking Alpha] 7.9%
TOP News Decliners
2/27
Form 4 CEL SCI CORP For: Feb 26 Filed by: PRICHEP PATRICIA B
-15.5%
5/16 The Dangers Of CEL-SCI Corporation [Seeking Alpha] -13.3%
4/1 Form 4 CEL SCI CORP For: Mar 31 Filed by: KERSTEN GEERT R -11.5%
3/9 CEL-SCI up 11% premarket on development of COVID-19 treatment [Seeking Alpha] -9.9%
3/23 CEL-SCI Announces Bought Deal Offering -9.5%
10/24 CEL-SCI Corporation Issues Letter to Shareholders -8.7%
8/27 CEL-SCI: A Risky Bet [Seeking Alpha] -7.4%
3/13 Form POS AM CEL SCI CORP -6.7%
10/14 Bearish CEL-SCI Article Ignored Scientific Evidence And Misinterpreted Multikine's Clinical Trial Design [Seeking Alpha] -6.4%
1/15 Cel-Sci Corporation (NASDAQ: CVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.2%
5/16 The Dangers Of CEL-SCI Corporation [Seeking Alpha] -13.3%
4/1 Form 4 CEL SCI CORP For: Mar 31 Filed by: KERSTEN GEERT R -11.5%
3/9 CEL-SCI up 11% premarket on development of COVID-19 treatment [Seeking Alpha] -9.9%
3/23 CEL-SCI Announces Bought Deal Offering -9.5%
10/24 CEL-SCI Corporation Issues Letter to Shareholders -8.7%
8/27 CEL-SCI: A Risky Bet [Seeking Alpha] -7.4%
3/13 Form POS AM CEL SCI CORP -6.7%
10/14 Bearish CEL-SCI Article Ignored Scientific Evidence And Misinterpreted Multikine's Clinical Trial Design [Seeking Alpha] -6.4%
1/15 Cel-Sci Corporation (NASDAQ: CVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: